Susceptibility test to second line drugs and re-treatment of tuberculosis. Revisiting early experiences;Las pruebas de sensibilidad a drogas de segunda línea y el re-tratamiento de la tuberculosis. Visión retrospective de tres estudios

Medicina

Volumn 67, Issue 3, 2007, Pages 231-237

  de Kantor, Isabel N ^a,c   Barrera, Lucia ^b  

^a OMS   (Argentina)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c NONE   (Argentina)

Author keywords

Argentina; Drug susceptibility tests; Multi drug resistance; Second line anti tuberculosis drugs; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; VIOMYCIN;

ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CHOICE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; REPRODUCIBILITY; TUBERCULOSIS; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FOLLOW UP; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STANDARD;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; ARGENTINA; CLINICAL TRIALS AS TOPIC; CYCLOSERINE; DRUG THERAPY, COMBINATION; ETHIONAMIDE; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 34447523849     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Centers of Disease Control. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
2. Toungoussova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis. 2005; 24: 202-6.
3. World Health Organization. Anti-tuberculosis drug resistance in the world. Report 3. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2004.343. Geneva: WHO, 2004, 299 pp.
4. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. NEJM 2003; 348: 119-28.
5. Grosset J. Systematic drug susceptibility testing: a necessary component of the "DOTS Plus" strategy? Int J Tuberc Lung Dis 1999; 3: 549-50.
6. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-81.
7. Laszlo A, Rahman M, Espinal M, et al. Quality assurance program for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/ IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-56.
8. Canetti G, Rist N, Grosset J. Mésure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneum 1963; 27: 217-72.
9. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
10. Canetti G, Grosset J. Téchniques et Indications des Examens Bactériologiques en Tuberculose. St. Mandé (France): Editions de la Tourelle, 1969, 192 pp
11. NCCLS. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; Tentative Standard-Second Ed. NCCLS document M24-T2[ISBN1-56238-423-6]. Wayne, Pennsylvania: NCCLS, 2000, 81 pp.
12. Pfyffer GE, Bonato DA, Ebrahimzade A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460. Technique and the proportion method with solid media J Clin Microb, 1999; 37: 3179-86.
13. Heifetz LB. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton: CRC Press, 1991, 212 pp.
14. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
15. Barreto AM, Araujo JB, Melo Medeiros RF, Souza Caldas PC. Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT System. Mem Inst 0swaldo Cruz 2003; 98: 827-30.
16. Martin A, Camacho, M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: Rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-9.
17. Morcillo N, Di Giulio B, Testani B, Pontino M, Chirico C, Dolmann A. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents Int J Tuberc Lung Dis 2004; 8: 253-9.
18. Parsons, L. M., Somoskovi, A., Urbanczik, R., Salfinger, M. Laboratory diagnostic aspects of drug resistant tuberculosis. Frontiers in Bioscience 2004; 9: 2086-105.
19. Huang TS, Lee SS, Tu HZ, et al. Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide. J Antimicrob Chemother. 2004; 53: 600-3.
20. Kim SJ, Espinal MA, Abe C, et-al. Is second-line antituberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004; 8: 1157-8.
21. Rey JC, Cetrángolo A, Dubra FA. Resistencia bacteriana a las drogas antituberculosas subsidiarias. Medicina (Buenos Aires) 1964; 24: 273-6.
22. Cetrángolo A, Di Lonardo M, de Kantor IN. Resistencia del Mycobacterium tuberculosis a algunas drogas antituberculosas subsidiarias o de segunda línea. Actas Xo. Congreso Argentino de Tisiología y Neumonología, Mar del Plata, Argentina, noviembre 1965, p162-5.
23. Cetrángolo A, Di Lonardo M, de Kantor IN, Isola NC. Bacteriología de los enfermos tuberculosos hospitalizados eliminadores de Mycobacterium tuberculosis resistentes a drogas subsidiarias. Actas del XI Congreso Argentino de Tisiología y Neumonología, Buenos Aires, octubre 1967, p 273-5.
24. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. In: whqlibdoc.who.int/publications/2006/9241546956_eng.pdf Consulted Jan 25, 2007.
25. Canetti G, Rist N, Grosset J, Cetrángolo A. Une simplification technique de la méthode des proportions pour tests de sensibilité du bacille tuberculeux: l'emploi d'une anse de platine. Arch Inst Pasteur Alger, 1964, 42: 14-8.
26. Canetti G. Bases biológicas para el tratamiento de la tuberculosis con las drogas menores (Conferencia, traducción al castellano por G.Amadio). Actas del IX Congreso Argentino de Tisiología y Neumonologia, Octubre 1963, Córdoba, Argentina, p 543-8.
27. Lefford MJ, Mitchison DA. Comparison of methods for testing the sensitivity of Mycobacterium tuberculosis to ethionamide. Tubercle, Lond. 1966; 47: 250-62.
28. Rich ML, Socci AR, Mitnick CD, et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006; 10: 290-6.
29. Vilcheze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD+ ratio mediates co-resistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 2005; 49: 708-20.
30. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates Antimicrob Agents Chemother. 2003; 47: 3799-805.
31. McClatchy JK, Kanes W, Davidson PT, Moulding TS. Cross-resistance in Mycobacterium tuberculosis to kanamycin, capreomycin and viomycin. Tubercle. 1977; 58: 29-34.
32. Communicable Diseases/World Health Organization. Guidelines for drug susceptibility testing for second-line anti tuberculosis drugs for DOTS-PLUS. Treatment of Multidrug-Resistant Tuberculosis. Geneva: WHO/ CDS/TB/2001.288, 2001. En: www.who.intr/infectous-disease-news/ IRCcatalogue/PDF/irccat2001-1.pdf Consulted Jan 8, 2007.
33. Mitchison DA. Drug resistance in tuberculosis. Eur Respir J 2005; 25: 376-9.